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Background: Advanced age has been traditionally considered a relative contraindi-
cation for heart transplantation. Older patients are now considered as potential
candidates for heart transplantation. The objective of this study was to evaluate the
long-term results of heart transplantation in patients older than 60 years.
Methods: Between 1986 and 2001, 81 patients aged between 60 and 70 years (mean,
63  2 years) underwent heart transplantation. These patients were compared with
403 adult recipients younger than 60 years (mean, 47  11 years) who underwent
transplantation during the same period.
Results: Thirty-day mortality was 6% (5/81) and 6% (25/403) in the older and
younger patients, respectively (P NS). Actuarial survival at 1, 5, and 10 years was
88% 4% versus 83% 2%, 75% 5% versus 69% 2%, and 50% 9% versus
51%  3% in the older and younger patients, respectively (P  NS). Older patients
had significantly fewer rejection episodes (P  .003). Freedom from allograft
coronary artery disease at 1, 5, and 10 years was 98% 2% versus 92% 2%, 85%
 6% versus 76%  3%, and 81%  7% versus 68%  3% (P  .1). The
incidences of infectious complication, cytomegalovirus infection, and posttransplant
lymphoproliferative disorder were similar between the 2 groups, but older recipients
were more likely to have a nonposttransplant lymphoproliferative disorder cancer (P
 .002). Age at transplantation was not identified as an independent risk factor for
early and late death.
Conclusion: Heart transplantation in selected patients aged 60 years and older results
in survival comparable with that of younger patients. Older patients have a lower
risk of rejection but an increased risk of development of a nonposttransplant
lymphoproliferative disorder cancer. Advanced age per se should not be considered
as an exclusion criterion for transplantation.
Initially, heart transplantation was restricted to patients younger than 50years of age.1 After 1981, when cyclosporine (INN: ciclosporin) wasintroduced, survival after heart transplantation progressively improved, andrecipient selection criteria became less restrictive. These evolving selectioncriteria included a progressive extension of the upper age limit for potentialcandidates, initially up to 60 years and ultimately up to and above 70 years.
Support for criteria relaxation came mostly from small single-center studies de-
scribing equivalent short-term survival, as well as lower rejection rates, in older
recipients.2-5 However, other authors have reported reduced survival after trans-
plantation in patients older than 60 years.6 Moreover, the Registry of the Interna-
tional Society for Heart and Lung Transplantation (ISHLT) is still reporting in-
creasing recipient age as a strong risk factor that adversely affects 1- and 5-year
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survival after heart transplantation.7 At Stanford University,
the heart transplantation program was initiated in 1968,8,9
and heart transplantation was offered to selected patients
aged 60 years and older starting in 1986 if these patients
were otherwise acceptable candidates for transplantation.
Today, considering the limited availability of donor organs
and the advent of new concepts, such as left ventricular
assist device technology as a definitive therapy for end-
stage congestive heart failure10 and alternate recipient lists
for heart transplantation,11 determination of the optimal
therapeutic option in patients older than 60 years presenting
with end-stage heart failure is more challenging than ever.
The objective of this study was to evaluate the long-term
results of cardiac transplantation in patients aged 60 years
and older to facilitate the determination of appropriate re-
cipient selection guidelines.
Patients and Methods
Patients
Between October 1986 and July 2001, 484 consecutive adult
patients (18 years) underwent primary orthotopic heart trans-
plantation at Stanford University Medical Center. Patients were
divided into groups according to the recipient’s age at the time of
transplantation: 81 (17% of total) patients were aged 60 years and
older (mean age, 63  2 years; range, 60-70 years; 15 patients
were older than 65 years), and 403 patients were aged between 18
and 59 years (mean age, 47  11 years). Pretransplantation eval-
uation of the recipients was the same in all patients: we used the
same eligibility criteria in older and younger patients. In patients
older than 50 years, evaluation involved an assessment of clinical
conditions commonly seen with advancing age, such as malignan-
cies, carotid and peripheral vascular disease, and end-organ dys-
function caused by diabetes mellitus. Although difficult to evaluate
quantitatively with the available data, a selection bias was clearly
present in the evaluation of older candidates to avoid selecting
borderline recipients with several risk factors in addition to ad-
vanced age.
The preoperative characteristics of the 2 groups are listed in
Table 1. Older patients were more likely to have ischemic cardio-
myopathy as the indication for transplantation (52% vs 35%), but
this difference did not reach statistical significance. The patients
older than 60 years had a higher prevalence of previous sternotomy
(61% vs 39%, P  .01), and their mean waiting time before
transplantation was significantly longer (219 vs 156 days, P 
.01). However, there was no significant difference in the other
TABLE 1. Preoperative characteristics of 484 consecutive adult patients undergoing first heart transplantation subdivided
according to age at transplantation
All patients (n  484) 18-60 y (n  403) >60 y (n  81)
N % N % N %
Age (y) 50  12 47  11† 63  2†
Range 18-70 18-59 60-70
Sex
Male 398 82 326 81 72 89
Female 86 18 77 19 9 11
Race
White 379 78 312 77 67 83
Other 105 22 91 23 14 17
BMI 25  4 25  4 25  4
BMI 19 26 5 24 6 2 3
BMI 31 44 9 36 9 8 10
Cardiomyopathy
Ischemic 184 38 142 35 42 52
Idiopathic 225 47 195 48 30 37
Other 75 15 66 17 9 11
Transplant status (UNOS)
1 167 36 140 36 27 34
2 317 64 263 64 74 66
Preoperative support
Inotropes 121 26 97 25 24 30
LVAD 40 9 38 10 2 3
IABP 6 1 5 1 1 1
Previous sternotomy 204 42 155 39† 49 61†
PRA 10 26 5 24 6 2 3
CMV positive 291 60 234 58 57 70
Waiting time (d) 168  203 156  195† 219  229†
BMI, Body mass index; UNOS, United Network for Organ Sharing; LVAD, left ventricular assist device; IABP, intra-aortic balloon pump; PRA, panel reactive
antibodies; CMV, cytomegalovirus.
*P  .05, †P  .01 by either (2) or t test.
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preoperative variables, including United Network for Organ Shar-
ing (UNOS) status at the time of transplantation and preoperative
use of inotropes or mechanical support.
Donor selection criteria were the same for all patients, and
allocation was made according to UNOS status and waiting time.
No effort was made to match older or so-called marginal donor
hearts with older recipients. Donor characteristics for the 2 groups
are listed in Table 2. Donors older than 50 years were used for 5%
of the younger patients and 9% of the older patients (P  NS).
Patients 60 years and older were more likely to get an organ from
a nonwhite donor (37% vs 24%, P  .01). However, the propor-
tion of female donors, sex mismatch (female donor to male recip-
ient), race mismatch, and weight mismatch (donor/recipient weight
ratio 0.80) were not statistically different between the 2 groups.
Surgical Technique
All donor hearts were harvested with cold hyperkalemic crystal-
loid Stanford solution, and cold storage was used during transpor-
tation. The donor cardiectomy and the technique of orthotopic
cardiac replacement have not changed significantly since its initial
description by Lower and Shumway.12 However, a bicaval im-
plantation technique has been used since 1996 in all patients. There
was no significant difference in mean allograft ischemic time and
cardiopulmonary bypass time between the 2 groups (Table 3).
Immunosuppressive Protocol
Immunosuppression consisted of induction therapy with RATG or
OKT3 (introduced in July 1987) and maintenance immunosup-
pression with cyclosporine, azathioprine, or mycophenolate
mofetil (introduced in January 1997) and steroids.9 Immunosup-
pressive protocols were the same for the younger and older pa-
tients.
Definitions and Follow-up
Acute rejection was diagnosed on the basis of histologic studies of
the endomyocardial biopsy specimens. Rejection severity was
graded according to the ISHLT rejection grading system.13 Infec-
tion was defined as any infection requiring intravenous antibiotics.
Allograft coronary artery disease was diagnosed on the basis of
coronary angiography and more recently with intravascular coro-
nary ultrasonography or at autopsy. Any lesion causing 50% or
greater stenosis in at least one major coronary artery was consid-
ered significant. Early death was defined as any death occurring
within the first 90 days after transplantation.
Patients and their primary care physicians were contacted pe-
riodically, and clinical data were entered prospectively in the
Stanford Transplant Database. Follow-up was 100% complete and
averaged 68 53 months for the entire series (maximal follow-up,
15.9 years; 244 patients still at risk at 5 years and 103 patients at
risk at 10 years).
Statistical Analysis
Continuous variables are reported as means  SD, and categoric
variables are reported as proportions and percentages. Compari-
sons between continuous variables were made by using the un-
paired 2-tailed t test. Categoric variables were compared by using
the 2 test. The actuarial life-table method was used to generate
survival estimates, which are reported with 95% confidence limits.
A log-rank test was used to compare survival estimates between
groups. A multivariable forward stepwise Cox proportional haz-
ards model was used after exploratory analysis of 28 recipient and
donor variables (Appendix 1) to identify independent risk factors
for early and late deaths. The P value for inclusion and retention
of variables in the models were .10 and .08, respectively. All
TABLE 2. Donor characteristics of 484 consecutive adult patients undergoing first heart transplantation subdivided
according to age at transplantation
All patients (n  484) 18-60 y (n  403) >60 y (n  81)
N % N % N %
Age (y) 30  11 30  11 30  11
Donor age 50 y 25 5 18 5 7 9
Sex
Male 364 75 301 75 63 78
Female 120 25 102 25 18 22
Sex mismatch 71 15 59 15 12 15
Race
White 357 73 306 76 51 63
Other 127 27 97 24† 30 37†
Race mismatch 183 38 150 37 33 41
Weight (kg) 77  15 77  16 78  13
D/R weight ratio 0.80 29 6 24 6 5 6
Cause of death
Trauma 346 71 292 72 54 67
CVA 96 20 75 19 21 26
Other 42 9 36 9 6 7
CMV mismatch 101 22 86 23 15 19
D/R, Donor/recipient; CVA, cerebrovascular accident; CMV, cytomegalovirus.
*P  .05, †P  .01 by either (2) or t test.
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statistical analyses were performed with the SPSS program (ver-
sion 10.0; SPSS Inc, Chicago, Ill).
Results
Perioperative Results
Thirty-day mortality was 6% (5/81) in the patients aged 60
years and older and 6% (25/403) in the younger patients (P
 NS, Table 3). Mean hospital stay was similar in both
groups (Table 3).
Survival
Actuarial survival estimates at 1, 5, and 10 years for all
patients were 84%  2%, 70%  2%, and 51%  3%,
respectively (Figure 1). Actuarial survival at 1, 5, and 10
years was not statistically different between patients older
than 60 years and patients younger than 60 years (88% 
4% vs 83%  2%, 75%  5% vs 73%  2%, and 50% 
9% vs 51%  3%, respectively; Figure 2). Causes of death
in the older and younger recipients are listed in Table 4.
Multivariable Analysis for Early and Late Deaths
As shown in Table 5, the only significant independent
determinants of early death (90 days) were female donor,
previous sternotomy, and preoperative support with ino-
tropes. Multivariable analysis identified earlier era (1986-
1992), sex mismatch, racial mismatch, and ischemic cardio-
myopathy as independent risk factors for late death (90
days, Table 6). Increasing recipient age was not identified as
an independent risk factor for early and late death.
Acute Rejection
Patients aged 60 years and older had 2.0  1.1 acute
allograft rejection episodes per patient compared with 2.6
1.8 episodes per patient in younger recipients, a difference
that was statistically significant (P  .003, Table 7). More-
over, actuarial freedom from acute rejection at 3 months, 1
year, and 2 years was significantly higher in older patients
(49%  6% vs 33%  2%, 39%  6% vs 27%  2%, and
36%  6% vs 24%  2%; P  .01).
Infection
Actuarial freedom from any infection at 3 months and 1, 5,
and 10 years after transplantation was not significantly
different between older and younger patients. Moreover,
freedom from cytomegalovirus infection at 3 months and 1,
5, and 10 years was also similar in both groups (Table 7).
Allograft Coronary Artery Disease
Actuarial freedom from allograft coronary artery disease at
1, 5, and 10 years was 98%  2% versus 92%  2%, 85%
 6% versus 76% 3%, and 81% 7% versus 68% 3%
in older and younger patients, respectively, a difference that
failed to reach statistical significance (P  .1, Figure 3).
Posttransplant Lymphoproliferative Disorder and
Nonposttransplant Lymphoproliferative Disorder
Cancer
Actuarial freedom from posttransplant lymphoproliferative
disorder (PTLD) 1, 5, and 10 years after transplantation was
TABLE 3. Intraoperative and postoperative data of 484 consecutive adult patients undergoing first heart transplantation
subdivided according to age at transplantation
All patients (n  484) 18-60 y (n  403) >60 y (n  81)
N % N % N %
Ischemic time (min) 175  50 173  52 183  42
Ischemia 240 min 41 9 33 9 8 10
CPB time (min) 122  37 121  39 128  31
30-Day mortality 30 6 25 6 5 6
Hospital stay (d) 20  27 20  29 20  21
Follow-up (mo) 68  53 70  55 59  42
CPB, Cardiopulmonary bypass.
*P  .05, †P  .01 by either 2 or t test.
Figure 1. Actuarial estimates of survival after heart transplanta-
tion in all patients.
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97%  2% versus 99%  1%, 97%  2% versus 97% 
1%, and 97% 2% versus 93% 2% in older and younger
recipients, respectively (P  NS, Table 7). Actuarial free-
dom from non-PTLD cancer at 1, 5, and 10 years was 92%
 3% versus 99%  1%, 76%  6% versus 89%  2%,
and 68%  9% versus 80%  3% in the older and younger
patients, respectively, a difference that was statistically sig-
nificant (P  .002, Figure 4).
Discussion
Heart transplantation is the best treatment option for se-
lected patients with end-stage heart failure who have failed
medical therapy and are not amenable to other treatment
options. Because of the critical shortage of donor organs,
selection of candidates for transplantation is based on the
potential for maximal benefit in terms of functional recov-
ery and long-term survival. The upper age limit used to
select potential candidates for heart transplantation has sig-
nificantly changed over the last 20 years, and it is still a
matter of debate.14,15 According to the 2000 Report from
Figure 2. Actuarial estimates of survival after heart transplanta-
tion according to age at transplantation.
TABLE 4. Causes of death in 484 consecutive adult patients
undergoing first heart transplantation subdivided accord-
ing to age at transplantation
18-60 y
(n  403)
>60 y
(n  81)
N % N %
Acute graft failure 9 5 1 4
Acute rejection 17 10 3 13
Infection 45 27 5 21
Allograft coronary artery disease 27 16 3 13
Malignancy 24 14 3 13
Cerebrovascular accident 2 1 4 16
Other 40 24 6 25
TABLE 5. Independent risk factors for early mortality (<90
days) after heart transplantation according to Cox propor-
tional-hazards model
Variable  Hazard ratio 95% CL P value
Female donor 2.05 7.7 3.1-19.1 .001
Previous sternotomy 0.84 2.3 1.0-5.4 .05
Preoperative support
Inotropic drugs 0.99 2.7 1.2-6.3 .02
CL, Confidence limit.
TABLE 6. Independent risk factors for late mortality (>90
days) after heart transplantation according to Cox propor-
tional-hazards model
Variable  Hazard ratio 95% CL P value
Era 1986-1992 0.53 1.7 1.1-2.7 .02
Sex mismatch 0.64 1.9 1.1-3.2 .02
Race mismatch 0.38 1.5 1.0-2.2 .07
Ischemic cardiomyopathy 0.42 1.5 1.0-2.3 .05
TABLE 7. Postoperative morbidity of 484 consecutive adult
patients undergoing first heart transplantation subdivided
according to age at transplantation
18-60 y
(n  403)
>60 y
(n  81) P value
No. of rejection episodes 2.6 1.8 2.0 1.1 .003
Freedom from acute rejection (%) .01
3 mo 33 2 49 6
1 y 27 2 39 6
5 y 23 2 34 6
10 y 20 3 34 6
Freedom from any infection (%) NS
3 mo 58 3 60 6
1 y 38 3 39 6
5 y 25 3 33 6
10 y 24 3 30 6
Freedom from CMV infection (%) NS
3 mo 83 2 88 4
1 y 72 3 75 5
5 y 69 3 70 6
10 y 67 3 70 6
Freedom from PTLD (%) NS
1 y 99 1 97 2
5 y 97 1 97 2
10 y 93 2 97 2
Freedom from non-PTLD cancer (%) .002
1 y 99 1 92 3
5 y 89 2 76 6
10 y 80 3 68 9
NS, Not significant; CMV, cytomegalovirus.
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the Registry of the International Society for Heart and Lung
Transplantation, increasing recipient age remains an inde-
pendent risk factor that adversely affects 1- and 5-year
survival after heart transplantation, with a progressive in-
crease in risk when recipient age is greater than 55 years.7
Despite this, several centers no longer consider advanced
age as an absolute contraindication for heart transplantation
and are now accepting selected patients older than 60 years
when they are otherwise appropriate candidates for trans-
plantation. Appropriate evaluation and selection of these
elderly patients is obviously critical16 because several clin-
ical conditions, such as malignancies, are more commonly
seen in this age group,17 which might jeopardize survival
after transplantation. However, despite this change in eligi-
bility criteria over the years, few studies have evaluated the
long-term results of heart transplantation in older patients.
Initially, heart transplantation was restricted to patients
younger than 50 years.1,7 Later, as short- and long-term
survival after transplantation improved, selection criteria,
including age, were progressively liberalized in most heart
transplantation programs. Evidence for such change in up-
per age limit came from several studies reporting that mor-
bidity and mortality after heart transplantation were not
significantly increased in selected older patients.2-5 These
initial reports, however, were limited by small numbers of
patients and short-term follow-up. However, other authors
have subsequently reported that survival after heart trans-
plantation in patients older than 60 years was significantly
reduced, with an increase in the incidence of life-threatening
infectious complications and malignancies.6 Interestingly,
most of these early studies suggested that patients older than
60 years had fewer acute rejection episodes after transplan-
tation,2-6 and it was postulated that older recipients, having
decreased immune reactivity and reduced T-cell function,
might require less immunosuppression. Decreased immune
reactivity and increased susceptibility of the elderly patients
to the effects of immunosuppressive regimens have also
been proposed to explain the higher incidence of infectious
complications and malignancies after transplantation.6 More
recently, Borkon and colleagues18 reported that age greater
than 55 years at the time of transplantation was an indepen-
dent risk factor for late death in their contemporary series of
153 heart transplant recipients, with an estimated 5-year
survival of 56% in these patients compared with 78% in
patients younger than 55 years. These authors also observed
a greater incidence of life-threatening infections in older
recipients, with the same incidence of acute rejection in
younger and older patients. These results were not con-
firmed by other recent reports.19,20 Baron and coworkers19
reported their results in a series of 70 patients aged between
60 and 65 years transplanted over a period of 11 years and
noted similar survival in these patients and in patients
younger than 60 years transplanted during the same period,
without any difference between these 2 groups in the inci-
dence of infection and malignancy after transplantation.
At Stanford University, heart transplantation was offered
to selected patients aged 60 years and older starting in 1986
if these patients were otherwise acceptable candidates for
transplantation by using the same selection criteria as in
younger candidates. These recipients were listed on the
regular UNOS waiting list, and allocation of donor organs
was made according to UNOS status and waiting time. No
effort was made to match older or so-called marginal donor
hearts with older recipients. Immunosuppression protocol,
Figure 3. Freedom from allograft coronary artery disease (CAD)
after heart transplantation according to age at transplantation.
Figure 4. Freedom from non-PTLD cancer after heart transplan-
tation according to age at transplantation.
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infection prophylaxis, postoperative management, and mon-
itoring of rejection were the same in the older patients.
Older and younger patients were well matched for almost all
pretransplant recipient characteristics and donor character-
istics, except previous operation, which was more frequent
in the former, and waiting time, which was longer in the
older recipients. Despite these differences in baseline char-
acteristics, we found that perioperative mortality and hos-
pital length of stay were comparable in both groups. Mul-
tivariable analysis revealed that age at transplantation was
not an independent predictor of early death. Previous ster-
notomy, use of a female donor, and inotropic support at the
time of transplantation were the only independent risk fac-
tors for early death identified. Moreover, we observed that
long-term survival after transplantation was similar in the 2
groups. Similarly, age at transplantation was not identified
in the multivariable analysis as an independent risk factor
for late death. These results are consistent with those of
previously discussed series.3-5,19,20
As reported by several authors,3-6 the incidence of acute
rejection was lower in the older patients. In our series,
although not statistically significant, the incidence of allo-
graft coronary artery disease was lower in the patients older
than 60 years. Contrary to the results of some previous
reports,5,6,18 we did not find any difference in the incidence
of infectious complications and cytomegalovirus infection
in the 2 groups. However, even if the incidence of PTLD
was similar in the younger and older patients, the incidence
of non-PTLD cancer was significantly higher in the patients
aged 60 years and older. Despite this finding, the proportion
of death caused by cancer was comparable in the 2 groups.
Increasing age is a known risk factor for posttransplant
malignancies,17 and the importance of a thorough screening
program in the pretransplant evaluation of older candidates
and those with preexisting malignancies has already been
demonstrated.16 Taken together, these findings suggest that
patients older than 60 years might benefit from more strin-
gently tailored immunosuppression regimens.
Long-term survival in this series compares favorably
with the recently published midterm results of patients listed
on an alternate recipient list at UCLA and transplanted with
marginal organs.11 In the recent report from the REMATCH
investigators, survival of patients supported with a left ven-
tricular assist device as a definitive therapy for end-stage
heart failure was 52% at 1 year and 23% after 2 years11
compared with 88% and 82%, respectively, in the patients
older than 60 years in this series. Age greater than 65 years
was the most common reason for ineligibility for transplan-
tation and for enrollment in the REMATCH trial. On the
basis of these data, if transplantation had been offered to the
patients enrolled in REMATCH because of advanced age
only and who were allocated to the left ventricular assist
device arm, survival might have been improved.
A limitation of this study is the evolving nature of the
selection process of older potential candidates over 15
years. The eligibility criteria used were the same for all
patients, but a subjective selection bias was certainly present
in the evaluation of older patients to avoid selecting bor-
derline recipients with several risk factors in addition to
advanced age. Quantification of this bias was difficult be-
cause of incomplete data regarding the recipient acceptance
ratio over the 15-year period of this study. Also, the small
number of patients, especially those older than 65 years,
compared with numbers in large registry databases, such as
the ISHLT registry,7 limits the inferences made from these
results and increases the risk of a type II statistical error.
In summary, our experience with selected patients aged
60 years and older is favorable and indicates that heart
transplantation can be successfully performed in these pa-
tients, with long-term survival comparable with that seen in
younger patients. Age between 60 and 70 years per se
should not be considered an absolute contraindication to
heart transplantation, even in patients who have undergone
previous cardiac operation. Care must be taken in the pre-
transplant evaluation of patients older than 60 years to
identify concomitant medical condition that might limit
survival after transplantation. Finally, more strictly tailored
immunosuppression, with or without induction therapy,
might be beneficial in these patients to reduce the incidence
of non-PTLD malignancies.
We thank our surgical and medical colleagues, fellows, and
residents for their significant contributions to the Stanford Univer-
sity Heart Transplantation Program. They have all cared for a large
number of the patients described in the present report.
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Appendix 1. Pretransplantation and perioperative vari-
ables evaluated as potential independent risk factors for
early and late deaths in the multivariable analysis
Recipient variables
Age (y)
Recipient aged 60 y or older
Sex
Race
Weight (kg)
Body mass index
Low body mass index (19)
High body mass index (31)
Etiology of cardiomyopathy
Ischemic
Idiopathic
Congenital
Other
Previous sternotomy
Pretransplantation status
UNOS 1 A or B
UNOS 2
Preoperative support
None
Inotropic drugs
Left ventricular assist device
Intra-aortic balloon pump
Waiting time (d)
Panel reactive antibodies 10%
Pulmonary vascular resistance (Wood units)
Cytomegalovirus status
Donor variables
Age (y)
Donor older than 50 y
Sex
Race
Weight (kg)
Cause of death
Trauma
Cerebrovascular accident
Other
Cytomegalovirus status
Donor/recipient mismatch
Sex mismatch (female donor to male recipient)
Race mismatch
Donor/recipient weight ratio
Donor/recipient weight ratio 0.80
Cytomegalovirus status mismatch
Transplantation era
1986 to 1992
1993 to 2001
Demers et al Cardiothoracic Transplantation
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 1 231
TX
